John Newman
Stock Analyst at Canaccord Genuity
(1.28)
# 3,340
Out of 4,829 analysts
86
Total ratings
36%
Success rate
-14.33%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,152 → $850 | $574.70 | +47.90% | 16 | Apr 22, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.19 | +1,076.47% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $96.89 | +76.94% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $7.29 | +133.20% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.18 | +577.97% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $5.08 | +392.13% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $7.85 | +2,447.77% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $14.75 | +42.37% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $60.88 | +88.90% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.69 | +1,067.54% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $42.79 | +56.58% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $10.56 | +307.20% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $5.00 | +120.22% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.52 | +859.69% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $29.33 | +50.02% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,720 → $400 | $3.49 | +11,361.32% | 4 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $6.80 | +3,135.29% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $14.05 | +170.46% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $2.28 | +1,084.21% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $8.10 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Apr 22, 2025
Maintains: Buy
Price Target: $1,152 → $850
Current: $574.70
Upside: +47.90%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.19
Upside: +1,076.47%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $96.89
Upside: +76.94%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $7.29
Upside: +133.20%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.18
Upside: +577.97%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.08
Upside: +392.13%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $7.85
Upside: +2,447.77%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $14.75
Upside: +42.37%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $60.88
Upside: +88.90%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.69
Upside: +1,067.54%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $42.79
Upside: +56.58%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $10.56
Upside: +307.20%
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $5.00
Upside: +120.22%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.52
Upside: +859.69%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $29.33
Upside: +50.02%
Aug 10, 2021
Downgrades: Hold
Price Target: $1,720 → $400
Current: $3.49
Upside: +11,361.32%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $6.80
Upside: +3,135.29%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $14.05
Upside: +170.46%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $2.28
Upside: +1,084.21%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $8.10
Upside: -